Jasper Therapeutics
JSPR· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -91.4% in FY2025
Jeet Mahal is the CEO of Jasper Therapeutics and was paid $1.3M in FY2025 (Dec), up 1%.
Pay$100 in the stock at the end of FY21 → $2
Executives4
See all- 1Ronald MartellFormer Chief Executive Officer and PresidentFY2025
- 2Edwin Tucker, M.D.Former Chief Medical OfficerFY2025
- 3Jeet MahalChief Executive Officer and President; Former Chief Operating OfficerFY2025
- 4Herb CrossChief Financial Officer and Corporate SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allJasper Therapeutics paid its 4 named executives $6.6M in total in FY2025 (Dec). CEO Jeet Mahal was paid $1.3M of that.
| Name | |||
|---|---|---|---|
| Ronald MartellFormer Chief Executive Officer and President | |||
| Edwin Tucker, M.D.Former Chief Medical Officer | |||
| Jeet MahalChief Executive Officer and President; Former Chief Operating Officer | |||
| Herb CrossChief Financial Officer and Corporate Secretary |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Jasper Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Judith ShizuruDirector · 7 yr on the boardNot independentResearch and Development—Paid as an executive
- Scott BrunDirector · 2 yr on the boardIndependentCompensation, Research and Development (Chair)—Paid as an executive
- Svetlana LucasDirector · 1 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Jun 15, 2026 | FY2025 |
| Annual report | 10-K | Mar 30, 2026 | FY2025 |
| Proxy statement | DEF 14A | May 19, 2025 | FY2024 |
| Annual report | 10-K | Feb 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 22, 2024 | FY2023 |
| Annual report | 10-K | Mar 5, 2024 | FY2023 |
